CJC-1295

Synthetic GHRH analog that pairs with Ipamorelin for synergistic GH-pulse amplification.

Overview

CJC-1295 is a synthetic analog of the first 29 amino acids of growth hormone releasing hormone (GHRH), engineered for resistance to degradation. Two versions exist: "no DAC" (short half-life, ~30 min, pairs with ipamorelin for natural pulsatile release) and "with DAC" (drug affinity complex, 7-day half-life, tonic elevation). Community consensus strongly prefers no-DAC for most optimization protocols - pulsatile release is more physiologic.

The classic stack is CJC-1295 no-DAC 100–200 mcg + Ipamorelin 200–300 mcg injected together 1–3× daily. GHRH and GHRP act on different receptors (GHRH-R and GHSR) so combining them amplifies GH release beyond what either produces alone.

Response is similar to ipamorelin alone for IGF-1 elevation; the combination adds magnitude and improves consistency. Good for GH secretagogue newcomers who want a cleaner alternative to tesamorelin.

Mechanism of Action

CJC-1295 activates the GHRH receptor on the anterior pituitary, stimulating endogenous GH release. The "no DAC" version has a short half-life (~30 min), which preserves natural pulsatile GH rhythm. The "with DAC" version binds to albumin via its DAC moiety for extended half-life, producing tonic rather than pulsatile release.

Community Usage Patterns

No-DAC: 100–200 mcg SC, 1–3× per day, typically stacked with ipamorelin at same time points. Best on empty stomach. With DAC: 1–2 mg weekly or every 10 days. Most optimization protocols use no-DAC. 12-week cycles with IGF-1 check at 6–8 weeks.

Education only - not medical advice. Any protocol change should involve your licensed provider.

Deep Dive

The molecular engineering behind the two versions

Native growth hormone releasing hormone is a 44-amino-acid peptide, but its biological activity lives almost entirely in the first 29 residues, GHRH(1-29). In circulation that fragment survives only a few minutes because the enzyme dipeptidyl peptidase-4 (DPP-4) clips its N-terminus and inactivates it. Every compound in this family is an attempt to defeat that clock.

The version most optimization protocols actually inject, sold as "CJC-1295 no-DAC," is more precisely called **modified GRF(1-29)**. It carries four amino acid substitutions relative to native GHRH: a D-alanine at position 2 that blocks DPP-4 cleavage, plus changes at positions 8, 15, and 27 that block deamidation and methionine oxidation and add further resistance to enzymatic breakdown. Those swaps stretch the half-life from minutes to roughly 30 minutes, long enough to drive one clean GH pulse and short enough to clear before the next.

The "with DAC" version adds a **Drug Affinity Complex**: a maleimide-based linker that forms a covalent bond with cysteine-34 on circulating albumin. Tethered to a long-lived carrier protein, the peptide persists for about a week and produces a continuous GHRH signal rather than a discrete pulse. This single chemical difference, not any change to the active sequence, is why the two products behave like different drugs.

What the human evidence actually shows, and what it does not

Honesty about the evidence base matters here, because it is thinner than the compound's popularity suggests.

The one genuinely citable human trial is **Teichman et al., 2006** (Journal of Clinical Endocrinology and Metabolism), an ascending-dose safety and pharmacokinetic study of the DAC version in healthy adults. Single doses raised mean GH concentrations roughly 2- to 10-fold and IGF-1 roughly 1.5- to 3-fold, with IGF-1 effects persisting for one to two weeks and an estimated half-life near 6 to 8 days. That study established the pharmacology, but it was a short safety and dose-finding trial, not an outcomes study.

Critically, the no-DAC / modified GRF(1-29) product that dominates real-world protocols has essentially no dedicated published human clinical trial of its own. Its use is extrapolated from the DAC pharmacology above and from the broader GHRH-analog class, where sermorelin and the FDA-approved tesamorelin (studied in the randomized Egrifta trials for HIV-associated lipodystrophy) provide the closest human data. The clinical program for CJC-1295 itself was discontinued by its original developer, and the compound never reached regulatory approval, so there are no long-term human safety or outcome data for either version. Any claim about durable benefit rests on mechanism and short trials, not on long-run evidence.

The feedback ceiling: secretagogue versus injected HGH

A conceptual point shapes how people track this compound: CJC-1295 does not add growth hormone to the body. It signals the pituitary to release its own. That endogenous release stays subject to the body's own brakes, the inhibitory hormone somatostatin and negative feedback from IGF-1. GHRH analogs cannot override a somatostatin trough, which places a physiological ceiling on how high GH can be pushed and is the mechanistic argument for why this axis is generally considered more self-limiting than injecting recombinant HGH, which bypasses that feedback entirely.

This is also why no-DAC is generally preferred over DAC in practice. Natural GH secretion is pulsatile, and the pulsatility itself is part of the signal. A tonic, week-long GHRH signal from the DAC version can blunt the normal peaks and troughs and may reduce somatotroph responsiveness over time, whereas a short pulse more closely mimics native rhythm.

Biomarkers commonly tracked on a GH-secretagogue protocol

Because GH itself is pulsatile and nearly impossible to capture on a single random draw, tracking centers on the stable downstream markers:

- **IGF-1** is the workhorse. It integrates GH exposure over roughly a day and is stable enough to compare across draws. It is most informative read against age- and sex-adjusted reference ranges rather than a single cutoff. A widely cited tracking guardrail is keeping IGF-1 within a youthful-normal range rather than pushing it supraphysiologic, because epidemiology (notably the **Renehan et al. 2004 Lancet meta-analysis**) has linked high circulating IGF-1 to increased risk of certain cancers. That is an association in observational data, not a demonstrated effect of these peptides, but it is why the ceiling concept exists. - **IGFBP-3** is the main IGF-1 binding protein and is also GH-dependent, so it tends to move with IGF-1 and helps confirm a genuine axis response versus assay noise. - **Fasting glucose and fasting insulin** matter because growth hormone is counter-regulatory: it antagonizes insulin action and can nudge fasting glucose and HOMA-IR upward. Tracking both catches insulin-sensitivity drift early. - **Hematocrit** is monitored because GH and IGF-1 can modestly influence red-cell production and fluid balance.

All of these are markers to review with a licensed clinician, not thresholds to self-manage.

Regulatory and anti-doping status

CJC-1295 has no FDA-approved formulation in any version. There is no manufacturer, no standardized dose, and no purity guarantee, which is why circulating material is described as available only for research and why availability through compounding pharmacies has tightened as the FDA reviews peptide bulk substances. On this platform it is noted as Category 1 under the 2026 reclassification framework, but regulatory categorization for peptides is actively shifting and should be re-checked rather than assumed.

For competitive athletes the status is unambiguous: growth-hormone-releasing factors including CJC-1295 sit on the **World Anti-Doping Agency Prohibited List under class S2**, banned at all times, in and out of competition. Anyone subject to drug testing should treat it as prohibited. As with everything here, this section is educational and is not a recommendation to obtain or use the compound. Those decisions belong with a licensed clinician.

Biomarkers to Track

When running CJC-1295, these are the biomarkers most commonly tracked to assess response and safety:

Blood Work Checklist

Before starting CJC-1295, baseline the right panel. The Peptide Blood Work Checklist covers the full baseline panel, what to add for CJC-1295's class, and when to retest.

Reconstitution Calculator

Free calculator for CJC-1295 reconstitution math - vial size, BAC water volume, and exact syringe units.

Side Effects & Monitoring

What CJC-1295 side effects are commonly reported, when they appear, the red flags worth a provider call, and the biomarkers that catch issues early.

Results & What to Track

What CJC-1295 results actually look like in the data - the markers to measure, when they tend to move, and how to tell a real result from placebo.

Related Reading

• Ipamorelin Cjc 1295 Protocol →
• Igf 1 Blood Test Guide →

Related Peptides

Stacks That Include CJC-1295

CJC-1295 Head-to-Head Comparisons

Conditions CJC-1295 is Commonly Researched For

Frequently Asked Questions

Log doses, upload your lab PDFs, and let StackAI read your panel in context of what you're actually running. Free to start.